Oramed Pharmaceuticals
ORMP
39 hedge funds and large institutions have $6.18M invested in Oramed Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
48% more call options, than puts
Call options by funds: $730K | Put options by funds: $493K
23% more capital invested
Capital invested by funds: $5.01M → $6.18M (+$1.18M)
11% more funds holding
Funds holding: 35 → 39 (+4)
2.36% less ownership
Funds ownership: 8.52% → 6.15% (-2.4%)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$99K |
| 2 |
LPL Financial
San Diego,
California
|
+$46K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$43.9K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$41.7K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$483K |
| 2 |
Renaissance Technologies
New York
|
-$313K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$255K |
| 4 |
Millennium Management
New York
|
-$152K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$106K |
ORMP Hedge Fund Activity: Q4 2020 in Review
39 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2020, worth a combined $6.18M — up 23% from $5.01M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ORMP positions and 8 closed out — a net gain of 4 holders — while 5 added to existing stakes and 9 trimmed.
The largest buyer was Squarepoint, opening a new position worth an estimated $99K. The largest seller was Phoenix Financial, exiting entirely with an estimated $483K sold.
- 39 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2020, up from 35 in Q3 2020.
- Funds reported $6.18M of Oramed Pharmaceuticals stock for Q4 2020, up 23% quarter-over-quarter.
- 12 funds opened new Oramed Pharmaceuticals positions in Q4 2020 and 8 closed out, a net change of +4 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2020 was Squarepoint, an estimated $99K added.
- The largest Oramed Pharmaceuticals seller in Q4 2020 was Phoenix Financial, an estimated $483K sold.
Based on aggregated 13F filings for Q4 2020.